Abstract：
The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.
摘要：
转移性激素敏感型前列腺癌（mHSPC）的标准治疗现在是雄激素剥夺疗法加上雄激素受体靶向疗法（阿比特龙，阿帕鲁胺,恩扎鲁他胺或达鲁他胺)，有或没有化疗（多西他赛）。为每种治疗方法选择合适的患者已成为确保疗效和最小化副作用的决定因素。本文结合近期临床证据和肿瘤内科专家积累的经验,放射肿瘤学和泌尿外科,为mHSPC提供全面的观点和治疗建议。
